Immunoreaction of the head and neck carcinoma.

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K20230
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Otorhinolaryngology
• Research Institution: The University of Tokyo
• Principal Investigator: Saito Yuki 東京大学, 医学部附属病院, 助教 (40611009)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 頭頸部腫瘍 / 腫瘍免疫

Outline of Final Research Achievements

Background: The high sensitivity group of PD-1 inhibitors is considered to be a high tumor gene mutation burden (TMB) and a patient with a high T cell immune profile score (GEP). The clinical indicators of the high TMB and GEP group in head and neck squamous cell carcinoma is (HNSCC) unclear. Method: From the TCGA database, we measured TMB and GEP in 528 cases of head and neck squamous cell carcinoma and analyzed the relationship with clinical indicators. Papillary thyroid carcinoma (PTC) (405 cases), lung cancer (LC) (408 cases), and malignant melanoma (MM) (345 cases) were used for comparison. From TMB and GEP analysis, (1) MM, LC has more cases of PD-1 inhibitor response than head and neck cancer (2) Aged, advanced larynggohypopharyngeal cancer, PD-L1 high expression cases are good candidate for PD-1 inhibitors

Free Research Field

頭頸部腫瘍

Academic Significance and Societal Importance of the Research Achievements

ゲノムデータを用いて臨床医のPD-1阻害剤選択に関わる因子を抽出したという点で非常に意義のある研究であると考えられる。TMBおよびGEPスコア算出方法に関しては多施設共同研究にも応用可能であると考えられる。